Here are the 10-K annual reports from Opko Health Inc. (OPK) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow OPK and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full OPK filings page.
OPKO Health files its annual report detailing a diversified healthcare business spanning pharmaceuticals and diagnostics. The company highlights NGENLA®, a once-weekly growth hormone partnered with Pfizer, which generated $31.9 million in 2025 royalty and profit-share payments and is approved in more than 50 countries.
OPKO emphasizes Rayaldee, an FDA‑approved treatment for secondary hyperparathyroidism, now launched or authorized across multiple international markets through partners VFMCRP and Nicoya. Its ModeX subsidiary is advancing multispecific antibody and vaccine platforms, supported by BARDA funding and collaborations with Merck and Regeneron.
In diagnostics, OPKO reshaped BioReference by divesting non-core assets to Labcorp for up to $462.5 million, cutting annual revenue by about $200 million but reducing headcount from roughly 3,300 to 1,373 and refocusing on New York/New Jersey clinical testing and the 4Kscore® prostate cancer test, whose revenue grew more than 13% in 2025.